MBRX
Moleculin Biotech, Inc.
Price Chart
Latest Quote
$2.17
-0.14 (-6.06%)
Current Price
| Previous Close | $2.31 |
| Open | $2.29 |
| Day High | $2.31 |
| Day Low | $2.16 |
| Volume | 102,365 |
Stock Information
| Shares Outstanding | 7.07M |
| Total Debt | $326K |
| Cash Equivalents | $10.32M |
| Net Income | $-42.37M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $15.33M |
| EPS (TTM) | $-15.31 |
| Exchange | NCM |
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.10 | 152,086 |
| 2026-07-16 | $2.17 | 102,400 |
| 2026-07-15 | $2.31 | 115,600 |
| 2026-07-14 | $2.26 | 125,900 |
| 2026-07-13 | $2.21 | 117,500 |
| 2026-07-10 | $2.28 | 139,200 |
| 2026-07-09 | $2.44 | 120,000 |
| 2026-07-08 | $2.37 | 216,000 |
| 2026-07-07 | $2.32 | 242,500 |
| 2026-07-06 | $2.40 | 406,500 |
| 2026-07-02 | $2.64 | 360,100 |
| 2026-07-01 | $2.69 | 680,500 |
| 2026-06-30 | $2.79 | 2,739,300 |
| 2026-06-29 | $3.57 | 2,016,200 |
| 2026-06-26 | $3.27 | 1,296,300 |
| 2026-06-25 | $2.99 | 600,700 |
| 2026-06-24 | $2.93 | 917,600 |
| 2026-06-23 | $2.75 | 11,238,800 |
| 2026-06-22 | $3.12 | 437,400 |
| 2026-06-18 | $2.88 | 379,200 |
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
đ° Latest News
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
Stocktwits âĸ 2026-06-30T18:52:03Z
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Benzinga âĸ 2026-05-13T16:41:46Z
Moleculin Biotech announces issuance of Canadian patent covering Annamycin
TipRanks âĸ 2025-09-26T12:45:39Z
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-09-17T16:00:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $25,103,000 | $26,641,000 | $29,631,000 | $30,640,000 |
| Other Income Expense | $-8,562,000 | $43,000 | $-1,506,000 | $1,375,000 |
| Other Non Operating Income Expenses | $-20,000 | $43,000 | $48,000 | $40,000 |
| Net Non Operating Interest Income Expense | $105,000 | $550,000 | $1,368,000 | $240,000 |
| Operating Expense | $25,103,000 | $26,641,000 | $29,631,000 | $30,640,000 |
| General And Administrative Expense | $9,122,000 | $8,786,000 | $10,017,000 | $11,542,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Net Interest Income | $105,000 | $550,000 | $1,368,000 | $240,000 |
| Interest Income | $105,000 | $550,000 | $1,368,000 | $240,000 |
| Normalized Income | $-25,018,000 | $-26,048,000 | $-28,215,000 | $-30,360,000 |
| Net Income From Continuing And Discontinued Operation | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Total Operating Income As Reported | $-25,103,000 | $-26,641,000 | $-29,631,000 | $-30,640,000 |
| Net Income Common Stockholders | $-33,664,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Net Income | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Net Income Including Noncontrolling Interests | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Net Income Continuous Operations | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Pretax Income | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Special Income Charges | $-614,000 | $0 | - | - |
| Interest Income Non Operating | $105,000 | $550,000 | $1,368,000 | $240,000 |
| Operating Income | $-25,103,000 | $-26,641,000 | $-29,631,000 | $-30,640,000 |
| Depreciation Amortization Depletion Income Statement | $90,000 | $126,000 | $127,000 | $130,000 |
| Depreciation And Amortization In Income Statement | $90,000 | $126,000 | $127,000 | $130,000 |
| Per Share | ||||
| Diluted EPS | $-28.42 | $-189.14 | $-376.75 | $-378.75 |
| Basic EPS | $-28.42 | $-189.14 | $-376.75 | $-378.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,471,000 | $-26,515,000 | $-27,950,000 | $-31,845,000 |
| Total Unusual Items | $-8,542,000 | $0 | $-1,554,000 | $1,335,000 |
| Total Unusual Items Excluding Goodwill | $-8,542,000 | $0 | $-1,554,000 | $1,335,000 |
| Reconciled Depreciation | $90,000 | $126,000 | $127,000 | $130,000 |
| EBITDA (Bullshit earnings) | $-25,013,000 | $-26,515,000 | $-29,504,000 | $-30,510,000 |
| EBIT | $-25,103,000 | $-26,641,000 | $-29,631,000 | $-30,640,000 |
| Diluted Average Shares | $1,184,569 | $137,720 | $79,024 | $76,278 |
| Basic Average Shares | $1,184,569 | $137,720 | $79,024 | $76,278 |
| Diluted NI Availto Com Stockholders | $-33,664,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Otherunder Preferred Stock Dividend | $104,000 | $0 | - | - |
| Other Special Charges | $614,000 | - | - | - |
| Gain On Sale Of Security | $-7,928,000 | $4,285,000 | $-1,554,000 | $1,335,000 |
| Research And Development | $15,891,000 | $17,729,000 | $19,487,000 | $18,968,000 |
| Selling General And Administration | $9,122,000 | $8,786,000 | $10,017,000 | $11,542,000 |
| Other Gand A | $9,122,000 | $8,786,000 | $10,017,000 | $11,542,000 |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,858,000 | $60,000 | $14,925,000 | $41,043,000 |
| Total Assets | $22,126,000 | $16,925,000 | $38,217,000 | $57,422,000 |
| Total Non Current Assets | $12,440,000 | $11,731,000 | $11,944,000 | $11,826,000 |
| Other Non Current Assets | $900,000 | - | - | - |
| Non Current Prepaid Assets | $900,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $11,148,000 | $11,148,000 | $11,148,000 | $11,148,000 |
| Other Intangible Assets | $11,148,000 | $11,148,000 | $11,148,000 | - |
| Current Assets | $9,686,000 | $5,194,000 | $26,273,000 | $45,596,000 |
| Prepaid Assets | $801,000 | $896,000 | $2,624,000 | $2,429,000 |
| Receivables | $7,000 | $20,000 | $99,000 | $22,000 |
| Other Receivables | $7,000 | $20,000 | $95,000 | $2,000 |
| Cash Cash Equivalents And Short Term Investments | $8,878,000 | $4,278,000 | $23,550,000 | $43,145,000 |
| Cash And Cash Equivalents | $8,878,000 | $4,278,000 | $23,550,000 | $43,145,000 |
| Debt | ||||
| Total Debt | $359,000 | $478,000 | $574,000 | $451,000 |
| Long Term Debt And Capital Lease Obligation | $222,000 | $358,000 | $474,000 | $335,000 |
| Current Debt And Capital Lease Obligation | $137,000 | $120,000 | $100,000 | $116,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,120,000 | $5,717,000 | $12,144,000 | $5,231,000 |
| Total Non Current Liabilities Net Minority Interest | $266,000 | $358,000 | $5,329,000 | $412,000 |
| Derivative Product Liabilities | $44,000 | $0 | $4,855,000 | $77,000 |
| Current Liabilities | $6,854,000 | $5,359,000 | $6,815,000 | $4,819,000 |
| Payables And Accrued Expenses | $6,717,000 | $5,239,000 | $6,715,000 | $4,703,000 |
| Payables | $3,508,000 | $2,030,000 | $2,558,000 | $2,181,000 |
| Accounts Payable | $3,508,000 | $2,030,000 | $2,498,000 | $2,095,000 |
| Equity | ||||
| Common Stock Equity | $15,006,000 | $11,208,000 | $26,073,000 | $52,191,000 |
| Total Equity Gross Minority Interest | $15,006,000 | $11,208,000 | $26,073,000 | $52,191,000 |
| Stockholders Equity | $15,006,000 | $11,208,000 | $26,073,000 | $52,191,000 |
| Gains Losses Not Affecting Retained Earnings | $10,000 | $-41,000 | $-9,000 | $12,000 |
| Other Equity Adjustments | $10,000 | $-41,000 | $-9,000 | $12,000 |
| Retained Earnings | $-206,004,000 | $-172,444,000 | $-131,604,000 | $-101,835,000 |
| Other | ||||
| Ordinary Shares Number | $3,199,228 | $135,155 | $89,100 | $76,340 |
| Share Issued | $3,199,228 | $135,155 | $89,100 | $76,340 |
| Tangible Book Value | $3,858,000 | $60,000 | $14,925,000 | $41,043,000 |
| Invested Capital | $15,006,000 | $11,208,000 | $26,073,000 | $52,191,000 |
| Working Capital | $2,832,000 | $-165,000 | $19,458,000 | $40,777,000 |
| Capital Lease Obligations | $359,000 | $478,000 | $574,000 | $451,000 |
| Total Capitalization | $15,006,000 | $11,208,000 | $26,073,000 | $52,191,000 |
| Additional Paid In Capital | $220,997,000 | $183,693,000 | $157,653,000 | $153,985,000 |
| Capital Stock | $3,000 | $0 | $33,000 | $29,000 |
| Common Stock | $3,000 | $0 | $33,000 | $29,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $222,000 | $358,000 | $474,000 | $335,000 |
| Current Capital Lease Obligation | $137,000 | $120,000 | $100,000 | $116,000 |
| Current Accrued Expenses | $3,209,000 | $3,209,000 | $4,157,000 | $2,522,000 |
| Net PPE | $392,000 | $583,000 | $796,000 | $678,000 |
| Gross PPE | $392,000 | $583,000 | $1,692,000 | $1,447,000 |
| Other Properties | $314,000 | $424,000 | $524,000 | $403,000 |
| Machinery Furniture Equipment | $78,000 | $159,000 | $1,168,000 | $1,044,000 |
| Dueto Related Parties Current | - | $130,000 | $60,000 | $86,000 |
| Accumulated Depreciation | - | $-1,022,000 | $-896,000 | $-769,000 |
| Duefrom Related Parties Current | - | $4,000 | $4,000 | $20,000 |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-22,735,000 | $-23,875,000 | $-23,715,000 | $-27,706,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,735,000 | $-23,862,000 | $-23,591,000 | $-27,639,000 |
| Cash Flow From Continuing Operating Activities | $-22,735,000 | $-23,862,000 | $-23,591,000 | $-27,639,000 |
| Operating Gains Losses | $8,542,000 | $-4,285,000 | $1,554,000 | $-1,335,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-13,000 | $-124,000 | $-67,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-13,000 | $-124,000 | $-67,000 |
| Capital Expenditure | - | $-13,000 | $-124,000 | $-67,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $25,765,000 | $4,660,000 | $4,166,000 | $0 |
| Financing Cash Flow | $27,284,000 | $4,635,000 | $4,141,000 | $-23,000 |
| Cash Flow From Continuing Financing Activities | $27,284,000 | $4,635,000 | $4,141,000 | $-23,000 |
| Net Other Financing Charges | $-8,000 | $-26,000 | $-25,000 | $-23,000 |
| Net Common Stock Issuance | $25,765,000 | $4,660,000 | $4,166,000 | $0 |
| Common Stock Issuance | $25,765,000 | $4,660,000 | $4,166,000 | $0 |
| Other | ||||
| End Cash Position | $8,878,000 | $4,278,000 | $23,550,000 | $43,145,000 |
| Beginning Cash Position | $4,278,000 | $23,550,000 | $43,145,000 | $70,903,000 |
| Effect Of Exchange Rate Changes | $51,000 | $-32,000 | $-21,000 | $-29,000 |
| Changes In Cash | $4,549,000 | $-19,240,000 | $-19,574,000 | $-27,729,000 |
| Proceeds From Stock Option Exercised | $1,527,000 | $1,000 | $0 | $0 |
| Net PPE Purchase And Sale | $0 | $-13,000 | $-124,000 | $-67,000 |
| Purchase Of PPE | $0 | $-13,000 | $-124,000 | $-67,000 |
| Change In Working Capital | $555,000 | $231,000 | $1,622,000 | $224,000 |
| Change In Payables And Accrued Expense | $1,347,000 | $-1,576,000 | $1,894,000 | $1,081,000 |
| Change In Accrued Expense | $17,000 | $-1,108,000 | $1,491,000 | $350,000 |
| Change In Payable | $1,330,000 | $-468,000 | $403,000 | $731,000 |
| Change In Account Payable | $1,330,000 | $-468,000 | $403,000 | $731,000 |
| Change In Prepaid Assets | $-792,000 | $1,807,000 | $-272,000 | $-857,000 |
| Other Non Cash Items | $-26,000 | $103,000 | $891,000 | $92,000 |
| Stock Based Compensation | $1,664,000 | $1,726,000 | $1,984,000 | $2,275,000 |
| Depreciation Amortization Depletion | $90,000 | $126,000 | $127,000 | $130,000 |
| Depreciation And Amortization | $90,000 | $126,000 | $127,000 | $130,000 |
| Gain Loss On Investment Securities | $8,542,000 | $-4,285,000 | $1,554,000 | $-1,335,000 |
| Net Income From Continuing Operations | $-33,560,000 | $-26,048,000 | $-29,769,000 | $-29,025,000 |
| Interest Paid Supplemental Data | - | - | - | - |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-07-17